Uncover key drivers, emerging technologies, and competitive movements shaping the human serum albumin market from 2025–2034 with trusted insights from The Business Research Company

How Much Will The Human Serum Albumin Market Be Worth By 2029?

The human serum albumin market has experienced significant growth in recent years. It is anticipated to increase from $5.39 billion in 2024 to $5.79 billion in 2025, achieving a compound annual growth rate (CAGR) of 7.5%. The expansion witnessed in the past can be attributed to several factors including rising healthcare demand, the broadening uses of human serum albumin, an expanding elderly population, an escalating need for blood plasma derivatives, and the increasing incidence of liver disorders and related conditions.

The human serum albumin market is projected to experience substantial expansion in the coming years. Its valuation is anticipated to reach $7.63 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 7.1%. This projected growth during the forecast period is primarily driven by factors such as increased availability of essential medicines, broader therapeutic applications, an increase in hospital numbers, enhanced healthcare infrastructure, and various governmental initiatives. Key trends influencing this period encompass cell-free protein synthesis, CRISPR-based strain engineering, the adoption of continuous manufacturing techniques, the development of transdermal delivery systems, and progress in lyophilization.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27310&type=smp

What External And Internal Drivers Are Influencing The Human Serum Albumin Market?

The human serum albumin market is projected to expand due to the escalating incidence of liver diseases. These conditions, which impair liver function, encompass hepatitis, fatty liver disease, cirrhosis, and liver cancer. The surge in liver diseases is attributed to the growing prevalence of obesity, as excess abdominal fat often results in non-alcoholic fatty liver disease (NAFLD), characterized by fat buildup, inflammation, and potential liver failure. Human serum albumin plays a crucial role in managing liver disease by restoring blood volume, mitigating fluid retention, safeguarding kidney function, and enhancing outcomes in associated complications such as ascites and hepatorenal syndrome. For instance, data from a report issued by the Office for Health Improvement & Disparities in July 2023 indicated a 22.0% increase in UK hospital admissions where liver disease was the primary diagnosis, climbing from 67,458 cases in 2021 to 82,290 cases in 2022. Consequently, the rising occurrence of liver diseases is a key driver for the human serum albumin market’s growth.

What Segmentation Insights Are Provided In The Human Serum Albumin Market Research?

The human serum albumin market covered in this report is segmented

1) By Type Of Preparation: Recombinant Human Serum Albumin, Plasma-Derived Human Serum Albumin

2) By Formulation Type: Injection Solutions, Lyophilized Powder

3) By Distribution Channel: Direct Sales, Online Pharmacies, Third-party Distributors, Hospital Pharmacies

4) By Application: Volume Expanders, Drug Delivery Systems, Nutrition Enhancement, Diagnostic Agents

5) By End-User: Hospitals, Research Laboratories, Pharmaceutical Companies, Blood Banks

Subsegments:

1) By Recombinant Human Serum Albumin: Yeast-Based Recombinant Human Serum Albumin, Bacterial-Based Recombinant Human Serum Albumin, Plant-Based Recombinant Human Serum Albumin, Mammalian Cell-Based Recombinant Human Serum Albumin, Insect Cell-Based Recombinant Human Serum Albumin

2) By Plasma-Derived Human Serum Albumin: 5% Human Serum Albumin Solution, 20% Human Serum Albumin Solution, 25% Human Serum Albumin Solution, Lyophilized Human Serum Albumin, Fatty Acid-Free Human Serum Albumin

Which Notable Trends Are Transforming The Human Serum Albumin Market Outlook?

Major companies operating in the human serum albumin market are actively pursuing the creation of innovative solutions, specifically animal-free recombinant excipients. These developments aim to improve product safety, ensure scalability, and meet regulatory requirements for biomanufacturing processes. An animal-free recombinant excipient is defined as a biologically engineered inactive substance, developed using recombinant DNA technology, entirely devoid of animal or human components, thereby guaranteeing high levels of purity and safety in both pharmaceutical and biomanufacturing contexts. As an illustration, InVitri Inc., a US-based supplier of animal-free, recombinant proteins and excipients, introduced Optibumin 25 in April 2025. This product stands as the first recombinant 25% human serum albumin developed for closed-system biomanufacturing. It is precisely optimized for processes like downstream processing, formulation, and cryopreservation workflows, and is currently offered in 100 mL single-use bags. Its composition, being free of animal origin and chemically defined, ensures exceptional purity, consistency, and minimizes the potential for contamination. Furthermore, it is GMP-ready, capable of scaling to commercial production volumes, and presents a stable, sterile solution that readily integrates into diverse applications, including viral vector manufacturing, stem cell preservation, vaccine formulation, and regenerative medicine.

Who Are The Leading Companies Driving The Human Serum Albumin Market?

Major companies operating in the human serum albumin market are Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, CSL Behring (CSL), Baxter International Inc., Grifols S A, Sartorius AG, Octapharma AG, Kedrion Biopharma, Shanghai RAAS Blood Products Co Ltd., Biotest Aktiengesellschaft, LFB Group, Hualan Biological Engineering Inc., Taibang Biologic Group, Kamada Ltd., InVitria Inc., Reliance Life Sciences, Bio Products Laboratory, Mitsubishi Tanabe Pharma, and Sichuan Yuanda Shuyang Pharmaceutical Co Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/human-serum-albumin-global-market-report

Which Geographic Regions Are Creating Strong Demand In The Human Serum Albumin Market?

North America was the largest region in the human serum albumin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human serum albumin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=27310&type=smp

Browse Through More Reports Similar to the Global Human Serum Albumin Market 2025, By The Business Research Company

Wall Decor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/wall-decor-global-market-report

Commercial Flooring Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/commercial-flooring-global-market-report

Exterior Wall Systems Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/exterior-wall-systems-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model